Balasia Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 56.69%
(FY 2023)
- Profit 90.22%
(FY 2023)
- Ebitda 75.76%
(FY 2023)
- Net Worth 38.32%
(FY 2023)
- Total Assets 0.45%
(FY 2023)
About Balasia Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sandeep Balasia and Deepak Balasia serve as directors at the Company.
- CIN/LLPIN
U74999WB2017PTC221472
- Company No.
221472
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Jun 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Balasia Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandeep Balasia  | Director | 13-Jun-2017 | Current |
| Deepak Balasia | Director | 13-Jun-2017 | Current |
Financial Performance of Balasia Pharmaceuticals.
Balasia Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 56.69% increase. The company also saw a substantial improvement in profitability, with a 90.22% increase in profit. The company's net worth Soared by an impressive increase of 38.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Balasia Pharmaceuticals?
In 2023, Balasia Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Satyam Conclave Private LimitedActive 13 years 4 monthsSandeep Balasia and Deepak Balasia are mutual person
- Mra Promoters Private LimitedActive 11 years 2 months
Sandeep Balasia and Deepak Balasia are mutual person
- Balasia Marketing Private LimitedActive 12 years 7 months
Sandeep Balasia and Deepak Balasia are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Balasia Pharmaceuticals?
Unlock and access historical data on people associated with Balasia Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Balasia Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Balasia Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
